Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Coexisting RET/PTC and TERT Promoter Mutation Predict Poor Prognosis but Effective RET and MEK Targeting in Thyroid Cancer.

The Journal of clinical endocrinology and metabolism - 18 Nov 2024

Zhang Wei, Lin Shuhuang, Wang Zhuo, Zhang Wenyong, Xing Mingzhao

Abstract excerpt

CONTEXT: The role of RET/PTC rearrangement in the clinical outcomes of papillary thyroid cancer (PTC) is controversial and remains to be clearly undefined. OBJECTIVE: This work aimed to investigate the role of coexisting RET/PTC rearrangement and TERT promoter mutation in the prognosis and therapeutic targeting in PTC. METHODS: A total of 669 PTC patients with complete clinical follow-up and genetic data were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Follow-Up Studies
Share to Gene Rearrangement

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Promoter Regions, Genetic

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-ret

Share to Telomerase

Share to Thyroid Cancer, Papillary

Share to Thyroid Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 38735658
DOI: 10.1210/clinem/dgae327
PMCID: PMC11570377

Genes

RET
TERT
BRAF
IMPACT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Coexisting RET/PTC and TERT Promoter Mutation Predict Poor Prognosis but Effective RET and MEK Targeting in Thyroid Cancer.PMID 38735658Read ↗

Impact of BRAF V600E and TERT Promoter Mutations on Response to Therapy in Papillary Thyroid CancerSemantic proximity Read ↗

Effects of Coexistent BRAFV600E and TERT Promoter Mutations on Poor Clinical Outcomes in Papillary Thyroid Cancer: A Meta-Analysis.Semantic proximity Read ↗

The predictive value of coexisting BRAFV600E and TERT promoter mutations on poor outcomes and high tumour aggressiveness in papillary thyroid carcinoma: A systematic review and meta-analysis.Semantic proximity Read ↗

Mortality Risk Stratification by Combining <i>BRAF</i> V600E and <i>TERT</i> Promoter Mutations in Papillary Thyroid CancerSemantic proximity Read ↗

Risk stratification by combining common genetic mutations and TERT promoter methylation in papillary thyroid cancer.Semantic proximity Read ↗

Preoperative Co-Mutation of BRAFV600E and TERT Promoter Predicts Tumor Aggressiveness and Recurrence-Free Survival in Papillary Thyroid Carcinoma.Semantic proximity Read ↗

BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.Semantic proximity Read ↗

Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma-A meta-analysis.Semantic proximity Read ↗

A six-genotype genetic prognostic model for papillary thyroid cancer.Semantic proximity Read ↗

Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients.Semantic proximity Read ↗

TERT promoter Mutation and Its Association with Clinicopathological Features and Prognosis of Papillary Thyroid Cancer: A Meta-analysis.Semantic proximity Read ↗

Interplay of BRAF and TERT promoter mutations and Ki67 proliferation index in papillary thyroid carcinoma in Central Asians.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.